PT
Panbela Therapeutics develops Polyamine Metabolic Inhibitors (PMIs) that target dysregulated polyamine levels in oncology and orphan diseases, specifically in pancreatic cancer and familial adenomatous polyposis. Their clinical trials, including the ASPIRE trial for metastatic pancreatic ductal adenocarcinoma, aim to provide effective treatment options for patients with urgent unmet medical needs.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Panbela Therapeutics develops Polyamine Metabolic Inhibitors (PMIs) that target dysregulated polyamine levels in oncology and orphan diseases, specifically in pancreatic cancer and familial adenomatous polyposis. Their clinical trials, including the ASPIRE trial for metastatic pancreatic ductal adenocarcinoma, aim to provide effective treatment options for patients with urgent unmet medical needs.